Apollo Hospitals (APOLLOHOSP) has reported a stellar financial performance for the third quarter of the 2025-26 fiscal year. The company recorded a consolidated net profit of ₹502.3 crores, reflecting a significant 35% increase compared to the same period last year. This growth was fueled by a 17% surge in consolidated revenue, which reached ₹6,477.4 crores. Market reaction to these results has been overwhelmingly positive. Shares of Apollo Hospitals climbed nearly 6% today, February 11, hitting a high of ₹7,640. The company’s market capitalization now stands at approximately ₹1.09 lakh crores. Investors were also rewarded with the announcement of an interim dividend of ₹10 per share, with the record date set for February 16. The hospital segment remains a powerhouse, posting a 14% revenue increase. Operational efficiency is high, with the hospital business maintaining EBITDA margins near 25%. Management has successfully improved profitability by focusing on complex cases, particularly in oncology and cardiology. Expansion is a central pillar of the current strategy. Apollo is on track to invest ₹8,000 crores to add 4,300 beds over the next four years. In the immediate pipeline, 700 new beds are expected to become operational in the coming months. Recent launches include a 250-bed facility in Pune, with additional upcoming capacity in Kolkata, Hyderabad, and Bengaluru. The Apollo HealthCo segment, which includes the digital platform and India’s largest pharmacy network, is nearing a critical financial milestone. Losses from the digital health business have narrowed significantly, and the online pharmacy division is expected to achieve EBITDA break-even by the end of this fiscal year. A major strategic restructuring is also underway. The company plans to merge its omnichannel pharmacy business with Keimed, a wholesale distributor. This new entity is projected to generate ₹25,000 crores in revenue by FY27 and is expected to be listed independently within the next 15 to 18 months. The broader Indian healthcare sector continues to show robust demand, with the market projected to grow at a CAGR of 17-22%. With a structural shortage of quality beds across India, Apollo is positioning itself to capture this demand through a mix of brownfield and greenfield projects, particularly targeting North India and Tier-2 cities. Analysts remain bullish, with approximately 86% maintaining a "Buy" rating. The stock's recent technical breakout above ₹7,565 suggests further potential upside, supported by strong institutional volume and improved earnings per share.